Priority areas in the assessment and treatment of CF exacerbations: Location, duration, inflammation

J Cyst Fibros. 2022 Jul;21(4):556-557. doi: 10.1016/j.jcf.2022.04.012. Epub 2022 Apr 28.

Authors

Suzanne C Carter¹, Edward F McKone²

Affiliations

¹ Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland.
² Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin 4, Ireland; School of Medicine, University College Dublin, Dublin 4, Ireland. Electronic address: emckone@svhg.ie.

PMID: 35491318
DOI: 10.1016/j.jcf.2022.04.012

No abstract available

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / therapeutic use
Cystic Fibrosis* / complications
Cystic Fibrosis* / diagnosis
Cystic Fibrosis* / therapy
Disease Progression
Humans
Inflammation / diagnosis
Inflammation / etiology
Inflammation / therapy

Substances

Anti-Bacterial Agents